Patents by Inventor Mun Kyung KIM

Mun Kyung KIM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230417748
    Abstract: Provided are a coronavirus spike (S) protein-specific antibody and use thereof.
    Type: Application
    Filed: November 5, 2021
    Publication date: December 28, 2023
    Inventors: Dong-Sik KIM, Sua LEE, Shin A JANG, Jihoon KANG, KI Joon CHO, Soo Bin PARK, Young Woo HAN, Hyemi NAM, Mi Young OH, Jee Boong LEE, Jihye RYU, Mun Kyung KIM, Jeewon LEE
  • Publication number: 20220162310
    Abstract: The present invention relates to: an antibody to T cell Immunoreceptor with Ig and Tyrosine-Based Inhibitory Motif Domains (TIGIT), or an antigen-binding fragment thereof; a nucleic acid encoding same; a vector carrying the nucleic acid; a cell transformed with the vector; a method for producing the antibody or the antigen-binding fragment thereof; and a composition and a composition for combined administration, which comprise same and are for preventing or treating cancer.
    Type: Application
    Filed: May 22, 2020
    Publication date: May 26, 2022
    Inventors: Hye-Young PARK, Eun Jung SONG, Eun Hee LEE, Hye In YUM, Hye Mi NAM, Mun Kyung KIM, Jee Won LEE, Joong Hyuk SHEEN, Min Kyu HUR, So Jung LIM, Ok Jae LIM, Yang Mi LIM, Jong Hwa WON
  • Publication number: 20220135679
    Abstract: A bispecific anti-GPNMB/anti-CD3 antibody specifically binds to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B) and uses thereof are disclosed. The bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.
    Type: Application
    Filed: April 6, 2020
    Publication date: May 5, 2022
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jae Chan PARK, Eun Jung SONG, So Jung LIM, Jae-Chul LEE, Hae Naem KWON, Su A LEE, Ok Jae LIM, Mun Kyung KIM, Hyun Jung CHO, Gil-Jung KIM, Jee Won LEE, Sung Keun KIM, Jong Wha WON, Shin A JANG
  • Publication number: 20200407713
    Abstract: The present invention relates to a transformed human cell and a use thereof and, more particularly, to a cell transformed with a gene for coding an MHC I cell membrane receptor and an MHC II cell membrane receptor by using a gene expression suppressing system using a guide RNA, and a use thereof. Such a transformed cell can effectively exhibit the therapeutic effect of cells even in vivo, and cannot be removed by an in vivo immune response. Therefore, it is expected that a composition comprising the immunocyte as an active ingredient can be usefully used for the treatment of cancer, infectious diseases, degenerative diseases or immunological diseases.
    Type: Application
    Filed: November 16, 2018
    Publication date: December 31, 2020
    Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Ok Jae LIM, Mun Kyung KIM, Yun Jung LEE, Jee Won LEE, Woo Seok YANG, Yu Young KIM, Yongin Eun KWON, Seung Hyon CHOE